Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Name: Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
Published: 2022
License: Public Domain

AbbVie · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

cancer multiple-myeloma

multiple myeloma, lemzoparlimab, abbv-imab-tjc4, relapsed or refractory multiple myeloma (r/r mm), cancer, tj011133, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Related documents